Tramadol Receives Expanded Indication in Canada for Moderately Severe Pain
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Tramadol Receives Expanded Indication in Canada for Moderately Severe Pain

NEW YORK -- August 25, 2008 -- The Therapeutic Products Directorate (TPD) in Canada has approved an expanded indication for once-daily tramadol (Ralivia) to include the treatment of moderately severe pain in addition to moderate pain.

The new indication is based on the results of 4 randomised, double-blind, parallel-group, placebo-controlled trials involving more than 3,000 patients and lasting 12 weeks. An additional study confirmed the safety and efficacy of tramadol administered for up to 58 weeks.

All participants of the trials presented with persistent, moderate-to-severe pain due to osteoarthritis of the knee and/or hip and low back pain.

Results showed that tramadol produced significant reductions in pain intensity relative to placebo as early as the first day of treatment, with analgesic efficacy increasing throughout the first 4 weeks of treatment.

Tramadol also produced significant improvements in sleep, including improvements in sleep quality, trouble falling asleep, and awakening by pain at night and in the morning.

Side effects include dizziness, nausea, constipation, and headache. Tramadol has a potential to cause psychic and physical dependence and should not be used in opioid-dependent patients.

SOURCE: Biovail

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities